Search

Your search keyword '"Ch'ng Sydney"' showing total 229 results

Search Constraints

Start Over You searched for: Author "Ch'ng Sydney" Remove constraint Author: "Ch'ng Sydney" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
229 results on '"Ch'ng Sydney"'

Search Results

1. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

3. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

4. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

5. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort

8. Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

10. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

27. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

28. Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients.

30. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

31. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

32. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

34. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

39. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

40. Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe

41. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

42. Abstract PR12: High-dimensional spatial analysis of the tumor-microenvironment to determine metastatic disease progression and response and resistance to therapy in head and neck cancer

43. Associations between patient‐level health literacy and diagnostic time intervals for head and neck cancer: A prospective cohort study.

44. Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma

45. Supplementary Figure from High-Dimensional and Spatial Analysis Reveals Immune Landscape–Dependent Progression in Cutaneous Squamous Cell Carcinoma

46. Supplementary Table from High-Dimensional and Spatial Analysis Reveals Immune Landscape–Dependent Progression in Cutaneous Squamous Cell Carcinoma

Catalog

Books, media, physical & digital resources